about
Comparison of Echocardiographic Measures in a Hispanic/Latino Population With the 2005 and 2015 American Society of Echocardiography Reference Limits (The Echocardiographic Study of Latinos).Association of Chronic Kidney Disease With Chronotropic Incompetence in Heart Failure With Preserved Ejection Fraction.Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction.Pulmonary hospitalizations and ischemic heart disease events in patients with peripheral artery disease.Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction.Tensor Factorization for Precision Medicine in Heart Failure with Preserved Ejection Fraction.Generation of human iPSCs from urine derived cells of patient with a novel heterozygous PAI-1 mutation.Generation of human iPSCs from urine derived cells of a non-affected control subject.Generation of human iPSCs from urine derived cells of a patient with a novel homozygous PAI-1 mutation.Changes in D-dimer and inflammatory biomarkers before ischemic events in patients with peripheral artery disease: The BRAVO Study.Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-β and Cardiac Fibrosis.A null mutation in SERPINE1 protects against biological aging in humans.Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview.Microvascular dysfunction and cardiac fibrosis in heart failure with preserved ejection fraction: a case report.Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment.Reply: Is Pump the Answer to Heart Failure With Preserved Ejection Fraction?Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial.RV Contractile Function and its Coupling to Pulmonary Circulation in Heart Failure With Preserved Ejection Fraction: Stratification of Clinical Phenotypes and Outcomes.Sudden Death in Heart Failure with Preserved Ejection Fraction: A Competing Risks Analysis from the TOPCAT Trial.Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients.A Prospective Pilot Study of Pocket-Carried Ultrasound Pre- and Postdischarge Inferior Vena Cava Assessment for Prediction of Heart Failure RehospitalizationAssessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial)Lack of Association Between Anemia and Intrinsic Left Ventricular Diastolic Function or Cardiac Mechanics in Heart Failure With Preserved Ejection FractionPhysical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial)Right Ventricular and Pulmonary Vascular Function are Influenced by Age and Volume Expansion in Healthy HumansTemporal Trends in Prevalence & Prognostic Implications of Comorbidities Among Patients with Acute Decompensated Heart Failure: The ARIC Study Community Surveillance
P50
Q30366671-C0B9D192-D232-41D1-8245-EA35CA86696CQ36054433-8B1D69D2-5273-4E64-8B68-269396C31C0FQ38682382-B6AEC3CC-5F5D-44EE-9E26-042816DC01E3Q38688215-30A5A9CE-4744-4569-834E-A8AF32843733Q38691846-31C0FFA1-4B58-44E4-BCF4-AC90B7153EAAQ39002974-EB7ABC3A-9957-4AE5-AF60-04DED234FCD2Q40249657-F9F77E71-2900-4C32-A930-E8E6CA783AD5Q40249665-D68820F4-754F-4667-AE7C-9D956988DBEAQ40416783-CE0E7D52-E7C1-4504-879C-007A8FF801B1Q41066125-820812AB-0396-48D6-9E3A-312D4A83ABD9Q45868567-972121A7-E56A-4E60-BBC9-D41B750C62E4Q45874700-9CCF2544-F676-42E2-AB0A-4962ECB3CEA0Q45947184-E1F96D1D-FEC7-4A35-BEAA-61876C763401Q49367785-F4FE02A6-894F-44A2-9D9F-545425A0996DQ50093822-2E277B85-C21B-450B-9577-FAF121635B2FQ51572725-50CB935F-38C7-4B06-9F24-B7795DEBCF9AQ52639539-5EAC2EFC-186F-4D04-BC28-D03870BD846DQ52680478-13123CE9-7844-4AB5-A9BC-99EA575A310EQ53825171-0714AAF2-D81C-4127-A2CD-9CE6C2094E43Q55330316-6E21068E-3F85-43AA-A244-678AFE4B31EEQ90776277-D1C79920-C3E4-48C4-B8C8-8CF92B9EE906Q90948055-5BD79D77-755E-4EFD-BF89-012945DDEB75Q91274822-2F8B59D0-2228-4132-83A8-8AC13B8F3283Q92398977-ABD29AB8-CBE3-411E-A74C-290824E378D9Q93345206-D3740C86-299D-4AE8-B1C4-2AA55ECF4F71Q96120608-1AC694A5-0285-4BE2-8C87-FEC635A53E9B
P50
description
researcher ORCID ID = 0000-0002-5655-8201
@en
wetenschapper
@nl
name
Sanjiv J Shah
@ast
Sanjiv J Shah
@en
Sanjiv J Shah
@nl
type
label
Sanjiv J Shah
@ast
Sanjiv J Shah
@en
Sanjiv J Shah
@nl
prefLabel
Sanjiv J Shah
@ast
Sanjiv J Shah
@en
Sanjiv J Shah
@nl
P31
P496
0000-0002-5655-8201